Developing medical countermeasures: from BioShield to BARDA

✍ Scribed by Jonathan B. Tucker

• Book ID: 102144716
• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 108 KB
• Volume: 70
• Category: Article
• ISSN: 0272-4391
• DOI: 10.1002/ddr.20299

✦ Synopsis

Abstract

The U.S. Congress passed the Project BioShield Act in 2004 to create market incentives for the private sector to develop medical countermeasures (MCMs) against high‐priority chemical, biological, radiological, and nuclear threats. Two years later, Congress patched recognized gaps in the BioShield legislation by adopting the Pandemic and All‐Hazards Preparedness Act of 2006, which established the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (DHHS). BARDA provides financial and managerial support for companies developing MCMs. This article examines U.S. government efforts in the MCM field and prospects for the future. Drug Dev Res 70:224–233, 2009. © 2009 Wiley‐Liss, Inc.